Latest pancreatitis Stories
The Firm is evaluating Byetta lawsuits on behalf of individuals who developed pancreatitis, pancreatic cancer or thyroid cancer allegedly due to their use of Byetta or other incretin mimetic Type
The Firm is evaluating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer due to their use of the medication. New
The Firm is actively investigating Januvia and Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis and other serious injuries after taking either of
The Firm is investigating Byetta lawsuits and other legal claims that allege incretin mimetics like Byetta, Januvia and Victoza caused patients to develop pancreatic cancer, pancreatitis or thyroid
Baptist Medical Center Jacksonville is the first hospital in the U.S.
- Combination of linagliptin and metformin significantly reduced blood glucose levels compared with linagliptin alone RIDGEFIELD, Conn. and INDIANAPOLIS, Aug.
The registry will bring together data from patients and cutting-edge researchers, all working to improve care and develop new and better therapies for individuals suffering from pancreatic diseases
The Firm is evaluating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer, due to their use of the Type 2 diabetes medication.
Pre-Settlement Case Funding Firm announces new program focus for plaintiffs of Byetta, as well as Actos, Januvia, and Victoza cases. LOS ANGELES, June 27, 2014 /PRNewswire/ -- Legal-Bay
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc analysis showing that patients with type 2 diabetes having treatment intensified with insulin glargine therapy while also being treated with JANUVIA® (sitagliptin) 100 mg once-daily had a lower incidence of nighttime (nocturnal) hypoglycemia compared to patients also receiving placebo.
- Emitting flashes of light; glittering.